Tuesday, May 16, 2023 11:21:07 AM
I picked up 6k shares today at 22.
Another use for GLP-1. My daughter has Down syndrome, OCD and Autism. About 3 years ago she was having meltdowns every day. I literally had to hold her down to keep her from hurting herself.
Eventually ended up putting her in respidone and upon raising dose every few months. That caused weight gain and in general she was just never the same as before the meltdowns started. I started her on semaglutide and B12 for the weight gain. With in 2 days she was back to smiling happy person that I had not seen in years.
I googled and found a few other cases that have had same results as my daughter.
Recent advances show that the gut-brain hormone ghrelin modulates aggressive behaviors. As the gut-brain hormone glucagon-like peptide-1 (GLP-1) reduces food intake and sexual behaviors its potential role in aggressive behaviors is likely. Therefore, we investigated a tentative link between GLP-1 and aggressive behaviors by combining preclinical and human genetic-association studies. Bla bla bla. The influence of acute or repeated injections of a GLP-1 receptor (GLP-1R) agonist. Overall, GLP-1 signaling suppresses acquisition of aggressive behaviors via central neurotransmission and additional studies exploring this link are warranted.
Another use for GLP-1. My daughter has Down syndrome, OCD and Autism. About 3 years ago she was having meltdowns every day. I literally had to hold her down to keep her from hurting herself.
Eventually ended up putting her in respidone and upon raising dose every few months. That caused weight gain and in general she was just never the same as before the meltdowns started. I started her on semaglutide and B12 for the weight gain. With in 2 days she was back to smiling happy person that I had not seen in years.
I googled and found a few other cases that have had same results as my daughter.
Recent advances show that the gut-brain hormone ghrelin modulates aggressive behaviors. As the gut-brain hormone glucagon-like peptide-1 (GLP-1) reduces food intake and sexual behaviors its potential role in aggressive behaviors is likely. Therefore, we investigated a tentative link between GLP-1 and aggressive behaviors by combining preclinical and human genetic-association studies. Bla bla bla. The influence of acute or repeated injections of a GLP-1 receptor (GLP-1R) agonist. Overall, GLP-1 signaling suppresses acquisition of aggressive behaviors via central neurotransmission and additional studies exploring this link are warranted.
Recent VKTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 08:48:01 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026 • PR Newswire (US) • 05/05/2026 11:05:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 06:21:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/30/2026 01:50:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 08:05:17 PM
- Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update • PR Newswire (US) • 04/29/2026 08:05:00 PM
- Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026 • PR Newswire (US) • 04/22/2026 08:35:00 PM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 04/10/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:15:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:14:56 PM
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 • PR Newswire (US) • 03/26/2026 11:05:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 03/05/2026 09:03:00 PM
- Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market • PR Newswire (US) • 02/13/2026 04:26:00 PM
- Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market • PR Newswire (Canada) • 02/13/2026 04:26:00 PM
- Viking Therapeutics jumps nearly 12% on plans to move oral obesity drug into Phase 3 • IH Market News • 02/12/2026 02:48:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 10:25:49 PM
- Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/11/2026 09:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:06:25 PM
- Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 • PR Newswire (US) • 02/04/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:57:19 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:55:53 AM
- Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity • PR Newswire (US) • 01/12/2026 12:00:00 PM
